recent
emerg
middl
east
respiratori
syndrom
coronaviru
human
outbreak
devast
porcin
epidem
diarrhea
coronaviru
swine
therapeut
intervent
urgent
need
howev
anticoronaviru
drug
current
avail
effort
assist
rapid
develop
anticoronaviru
drug
screen
nih
clinic
collect
cell
cultur
use
luciferas
reporterexpress
recombin
murin
coronaviru
compound
screen
found
signific
anticoronaviru
effect
experi
reveal
compound
block
viru
entri
other
inhibit
viral
replic
addit
valid
studi
top
inhibitor
hexachlorophen
nitazoxanid
homoharringtonin
demonstr
robust
anticoronaviru
activ
reduct
log
viru
titer
ic
rang
nm
lm
furthermor
homoharringtonin
hexachlorophen
exhibit
broad
antivir
activ
divers
speci
human
anim
coronavirus
sinc
nih
clinic
collect
consist
compound
alreadi
clinic
trial
small
molecul
inhibitor
great
potenti
rapid
develop
anticoronaviru
drug
coronaviru
envelop
rna
viru
singlestrand
positivesens
rna
genom
associ
nucleocapsid
n
protein
form
nucleocapsid
insid
envelop
fan
et
al
jayaram
et
al
spike
protein
protrud
virion
surfac
confer
viral
infect
major
determin
speciesand
tissuetrop
coronavirus
infect
human
divers
speci
anim
caus
respiratori
digest
neurolog
immunemedi
diseas
human
coronavirus
caus
mild
respiratori
ill
common
cold
enter
diseas
diarrhea
caul
eggleston
resta
et
al
zhang
et
al
new
coronaviru
term
sever
acut
respiratori
syndrom
sar
coronaviru
suddenli
emerg
human
popul
wild
anim
drosten
et
al
ksiazek
et
al
marra
et
al
rota
et
al
sicken
peopl
caus
death
cdc
sorensen
et
al
due
fear
caus
eas
humantohuman
transmiss
diseas
sever
high
mortal
sar
outbreak
pose
signific
threat
public
health
caus
devast
econom
loss
fortun
epidem
subsid
sar
reemerg
howev
anoth
new
coronaviru
term
middl
east
respiratori
syndrom
mer
coronaviru
recent
emerg
middl
east
spread
dozen
countri
lim
et
al
mitka
infect
peopl
claim
live
thu
far
origin
sar
mer
appear
distinct
respiratori
diseas
similar
high
mortal
rate
rais
renew
concern
mer
potenti
threat
public
health
global
scale
furthermor
although
exist
anim
coronavirus
widespread
new
coronaviru
strain
porcin
epidem
diarrhea
ped
coronaviru
emerg
sever
year
ago
asia
spread
america
includ
unit
state
stevenson
et
al
wang
et
al
caus
significantli
high
mortal
affect
piglet
new
epizoot
diseas
devast
swine
industri
countri
wipe
us
pig
popul
de
la
hamaid
howev
date
effect
drug
avail
treatment
coronaviru
infect
although
drug
test
vitro
altawfiq
et
al
barlough
shacklett
falzarano
et
al
morgenstern
et
al
saijo
et
al
effort
identifi
potenti
drug
capabl
inhibit
coronaviru
infect
present
studi
perform
vitro
screen
small
molecul
librari
nation
institut
health
clinic
collect
ncc
sar
mer
coronavirus
belong
biolog
genet
close
relat
betacoronaviru
subgroup
murin
coronaviru
use
recombin
murin
coronaviru
express
luciferas
report
gene
safe
surrog
evalu
anticoronaviru
efficaci
drug
preclin
andor
clinic
data
small
molecul
compound
alreadi
avail
identif
potenti
antivir
candid
allow
us
rapidli
advanc
process
discoveri
develop
effici
anticoronaviru
drug
screen
identifi
compound
anticoronaviru
properti
importantli
sever
compound
exhibit
robust
anticoronaviru
activ
micromolar
nanomolar
concentr
without
overt
cytotox
host
cell
thu
compound
advanc
anim
clinic
trial
potenti
develop
effect
anticoronaviru
drug
mous
astrocytoma
dbt
fibroblast
cell
cultur
dmem
contain
fetal
bovin
serum
fb
penicillin
unitsml
streptomycin
lgml
recombin
murin
coronaviru
mous
hepat
viru
mhv
strain
express
firefli
luciferas
term
de
haan
et
al
use
screen
throughout
studi
wildtyp
da
sarma
et
al
mhvjhm
also
use
experi
viru
titer
determin
standard
plaqu
assay
bovin
coronaviru
strain
zhang
et
al
human
enter
coronaviru
strain
zhang
et
al
grown
human
rectal
tumor
hrt
cell
monoclon
antibodi
mab
use
detect
mhv
n
protein
mab
n
protein
zhang
et
al
antibodi
bactin
purchas
invitrogen
goat
antimous
antivir
effect
drug
express
percent
luciferas
activ
control
data
repres
mean
independ
treatment
standard
deviat
mean
igg
conjug
horseradish
peroxidas
hrp
fitc
purchas
sigmaaldrich
ncc
librari
contain
total
small
molecul
drug
compound
suppli
plate
prepar
dmso
mm
http
wwwnihclinicalcollectioncom
screen
drug
first
transfer
new
plate
dilut
optimem
serumfre
medium
make
stock
plate
stock
transfer
well
anoth
plate
mix
give
final
concentr
lm
drug
drugviru
mixtur
deliv
well
infect
carri
h
vehicl
control
contain
dmso
primari
screen
duplic
plate
use
valid
screen
experi
conduct
triplic
plate
end
infect
cultur
medium
remov
cell
store
overnight
plate
allow
thaw
room
temperatur
dbt
cell
treat
hexachlorophen
variou
concentr
indic
dmso
vehicl
control
h
infect
moi
presenc
drug
h
cell
lyse
luciferas
assay
inhibit
mhv
infect
express
percent
reduct
luciferas
activ
follow
drug
treatment
compar
control
ic
calcul
indic
solid
line
c
inhibit
viral
titer
dbt
cell
treat
hexachlorophen
lm
dmso
control
h
infect
moi
h
medium
harvest
determin
viral
titer
tcid
data
indic
mean
replic
standard
deviat
mean
inhibit
viral
n
protein
express
experi
perform
ident
c
except
differ
concentr
drug
use
follow
drug
treatment
viral
infect
cell
lyse
evalu
viral
n
protein
express
level
western
blot
betaactin
serv
load
control
luciferas
reagent
ad
well
follow
gentl
shake
min
luciferas
activ
determin
use
synergi
micropl
reader
gen
softwar
biotek
data
export
excel
file
statist
analysi
cell
grown
plate
incub
h
drug
lm
cell
viabil
determin
use
xtt
assay
kit
accord
manufactur
instruct
sigmaaldrich
dmso
serv
vehicl
control
detect
protein
either
western
blot
analysi
ifa
perform
previous
describ
cao
zhang
viru
titer
determin
standard
tissu
cultur
infecti
dose
tcid
dbt
cell
plate
luciferas
data
librari
screen
plate
combin
use
statist
analysi
mean
luciferas
activ
replic
standard
deviat
sd
mean
calcul
standard
statist
method
express
percentag
neg
control
dmso
set
student
ttest
use
calcul
pvalu
statist
signific
strictli
standard
mean
differ
ssmd
zhang
use
select
candid
score
less
inhibitor
primari
screen
entir
ncc
librari
perform
dbt
cell
infect
duplic
plate
use
screen
ssmd
use
hit
select
rank
recent
ssmd
wide
use
hit
select
highthroughput
screen
assay
ht
sirna
small
molecul
screen
well
antivir
drug
select
andruska
et
al
aulner
et
al
gough
et
al
rachidi
et
al
zhang
neg
valu
ssmd
suggest
inhibitori
effect
posit
valu
indic
enhanc
effect
compound
ssmd
score
suggest
strong
inhibitori
effect
zhang
thu
use
score
cutoff
threshold
hit
select
result
show
drug
ssmd
score
less
indic
drug
like
antimhv
activ
drug
candid
exhibit
strong
inhibit
mhv
infect
ssmd
score
supplement
tabl
candid
anticoronaviru
drug
subject
valid
see
verifi
antivir
effect
candid
drug
secondari
screen
carri
dbt
cell
found
drug
respect
inhibit
mhv
infect
dbt
cell
supplement
tabl
specif
dbt
cell
drug
strongli
inhibit
viral
infect
ssmd
score
less
tabl
cell
viral
infect
strongli
inhibit
drug
exhibit
ssmd
score
less
tabl
cell
viabil
assay
reveal
candid
drug
significantli
decreas
cell
viabil
concentr
test
supplement
tabl
compar
analysi
reveal
candid
drug
exhibit
antivir
effect
dbt
cell
indic
differenti
cellular
target
may
play
role
viral
infect
supplement
tabl
importantli
candid
drug
commonli
effect
inhibit
viral
infect
dbt
cell
supplement
tabl
suggest
cellular
target
drug
conserv
two
cell
type
interestingli
mani
anticoronaviru
candid
drug
could
group
clinic
applic
abund
group
anticoronaviru
candid
drug
use
cancer
treatment
antidepress
antipsychot
supplement
tabl
evalu
whether
differ
moi
would
impact
outcom
screen
dbt
cell
treat
one
drug
benzbromaron
chloroxin
hexachlorophen
mitoxantron
nitazoxanid
dmso
h
infect
moi
h
presenc
respect
drug
shown
fig
compar
vehicl
dmso
control
reduct
luciferas
activ
similar
moi
indic
inhibitori
effect
candid
drug
mhv
infect
independ
moi
valid
statist
approach
employ
identifi
candid
drug
select
two
repres
drug
three
group
base
ssmd
score
low
median
high
determin
inhibitori
effect
viru
infect
inde
two
drug
homoharringtonin
hexachlorophen
lowest
ssmd
score
almost
complet
inhibit
coronaviru
infect
reduct
luciferas
activ
log
viru
titer
ribavirin
minoxidil
highest
ssmd
score
least
inhibitori
effect
viru
infect
reduct
luciferas
activ
log
viru
titer
two
drug
paroxetin
sertralin
median
ssmd
score
reduc
luciferas
activ
viru
titer
log
fig
thu
inhibitori
effect
drug
correl
invers
proport
ssmd
score
data
demonstr
gener
applic
ssmd
score
system
select
candid
drug
zhang
confirm
anticoronaviru
activ
candid
drug
select
toprank
drug
addit
studi
first
determin
ic
dbt
cell
infect
moi
treat
hexachlorophen
nitazoxanid
homoharringtonin
panel
fig
variou
concentra
tion
result
show
ic
vari
wide
nm
homoharringtonin
lm
hexachlorophen
nitazoxanid
antivir
effect
drug
clearli
dosedepend
complementari
altern
approach
luciferas
report
assay
also
perform
tcid
western
blot
dbt
cell
treat
drug
indic
concentr
h
infect
moi
h
pi
viral
titer
medium
determin
tcid
viral
n
protein
cell
assess
western
blot
expect
luciferas
report
screen
drug
robust
inhibitori
effect
viru
titer
reduct
log
hexachlorophen
homoharringtonin
fig
log
nitazoxanid
fig
consist
inhibit
viru
product
viral
n
protein
express
undetect
follow
treatment
hexachlorophen
lm
nitazoxanid
lm
homoharringtonin
nm
dosedepend
inhibit
viral
n
protein
egfp
report
gene
express
also
evid
fig
although
slight
variat
viral
inhibit
measur
method
compar
data
supplement
tabl
fig
overal
inhibitori
effect
select
drug
mhv
infect
firmli
establish
gain
insight
step
viru
life
cycl
target
candid
drug
sought
defin
whether
candid
drug
inhibitori
administ
infect
host
cell
sinc
origin
screen
involv
simultan
treat
infect
target
cell
evalu
postentri
effect
treat
cell
candid
drug
identifi
previou
screen
h
pi
h
determin
luciferas
activ
h
pi
result
show
drug
significantli
reduc
luciferas
activ
ssmd
homoharringtonin
duloxetin
chloroxin
hexachlorophen
ebselen
nitazoxanid
mitoxantron
disulfiram
ssmd
score
less
supplement
tabl
import
note
even
wellknown
antirna
viru
inhibitor
ribavirin
librari
rel
weak
inhibitori
effect
mhv
replic
ssmd
score
reduct
viru
titer
log
see
supplement
tabl
fig
suggest
sever
drug
identifi
may
potent
ribavirin
corrobor
find
second
set
experi
cell
treat
select
drug
h
prior
h
viru
infect
found
drug
strongli
inhibit
luciferas
activ
either
time
point
fig
agreement
result
obtain
use
luciferas
report
viru
egfp
express
also
drastic
inhibit
drug
ad
h
pi
fig
data
shown
data
indic
drug
inhibit
viru
infect
post
entri
stage
like
step
viral
replic
infecti
viral
particl
enter
cell
first
h
infect
mhv
biosynthesi
commenc
h
pi
dbt
cell
zhu
et
al
contrast
drug
inhibit
luciferas
activ
ssmd
drug
ad
h
pi
supplement
tabl
indic
drug
like
block
viral
entri
antivir
activ
establish
primari
secondari
screen
drug
treatment
viru
infect
carri
time
support
conclus
cell
treat
select
candid
drug
either
h
h
viru
infect
luciferas
activ
determin
h
pi
expect
candid
drug
inhibit
luciferas
activ
drug
ad
h
infect
inhibitori
effect
ad
h
pi
fig
interestingli
drug
clomid
oxaprozin
azathioprin
instead
enhanc
luciferas
activ
ad
h
pi
reason
enhanc
current
clear
consist
result
luciferas
assay
viral
gene
express
measur
egfp
report
express
strongli
inhibit
drug
ad
h
prior
infect
fig
extend
find
mhv
strain
util
sever
differ
mhv
strain
possess
variou
pathogen
phenotyp
cell
cultur
anim
exampl
jhm
strain
caus
extens
cell
fusion
dbt
cell
sever
enceph
demyelin
mice
strain
induc
cell
fusion
caus
encephalitisdemyelin
mice
da
sarma
et
al
hirano
et
al
phillip
et
al
thu
dbt
cell
treat
homoharringtonin
nm
h
infect
mhvjhm
moi
h
viral
n
protein
detect
western
blot
shown
fig
n
protein
mhv
strain
undetect
presenc
drug
control
untreat
sampl
express
n
protein
robust
data
suggest
homoharringtonin
capabl
inhibit
infect
variou
mhv
strain
furthermor
treatment
human
cell
homoharringtonin
hexachlorophen
prior
infect
bovin
coronaviru
human
enter
coronaviru
also
result
potent
inhibit
viral
n
protein
express
judg
immunofluoresc
analysi
fig
c
thu
extrapol
result
postul
great
number
candid
anticoronaviru
drug
identifi
screen
ncc
librari
like
broad
antivir
activ
human
anim
coronavirus
studi
identifi
substanti
number
candid
drug
exhibit
anticoronaviru
activ
worth
note
candid
drug
identifi
studi
previous
shown
inhibit
infect
virus
exampl
nitazoxanid
initi
discov
antiprotozo
activ
white
also
inhibit
infect
influenza
viru
hepat
b
viru
hbv
korba
et
al
hepat
c
viru
keeff
rossignol
japanes
enceph
viru
shi
et
al
noroviru
data
repres
mean
triplic
experi
standard
deviat
mean
b
cell
either
treat
drug
lm
indic
dmso
h
h
infect
moi
h
pi
egfp
express
observ
use
fluoresc
microscop
olympu
imag
captur
use
digit
camera
zeiss
siddiq
et
al
hexachlorophen
wide
use
disinfect
use
topic
antiinfect
antibacteri
agent
hexachlorophen
effect
inactiv
rotaviru
sattar
et
al
lm
inhibit
sarscov
replic
vero
cell
hsu
et
al
recent
report
demonstr
hexachlorophen
inhibit
bk
polyomaviru
simian
viru
infect
inhibit
atpas
activ
larg
antigen
seguin
et
al
benzbromaron
noncompetit
inhibitor
xanthin
oxidas
sinclair
fox
potent
inhibitor
hummel
et
al
use
treatment
gout
reinder
et
al
benzbromaron
also
inhibit
influenza
viru
infect
bind
pa
protein
decreas
viral
rna
polymeras
activ
fukuoka
et
al
pyrimidin
analog
inhibit
divers
virus
inhibit
viral
rna
synthesi
virus
inhibit
includ
anoth
human
coronaviru
pyrc
et
al
avian
coronaviru
infecti
bronchiti
viru
barlough
shacklett
footandmouth
diseas
viru
kim
et
al
tickborn
flavivirus
kyasanur
forest
diseas
viru
alkhurma
hemorrhag
fever
viru
omsk
hemorrhag
fever
viru
cranc
et
al
flint
et
al
west
nile
viru
morrey
et
al
homoharringtonin
inhibitor
translat
elong
also
inhibit
hbv
infect
vitro
romero
et
al
particular
note
find
studi
homoharringtonin
strongest
inhibitor
variou
coronavirus
lowest
ic
inhibitor
itraconazol
albendazol
nelfinavir
mesyl
artesun
inhibit
infect
de
gan
et
al
efferth
et
al
teba
powderli
walson
et
al
tetraethylthiuram
disulfid
inhibit
respiratori
syncytia
viru
semliki
forest
viru
vesicular
stomat
viru
boukhvalova
et
al
data
suggest
candid
drug
exhibit
broadspectrum
antivir
activ
overal
hit
rate
librari
screen
approxim
rate
inde
high
compar
previou
screen
raw
chemic
librari
howev
high
hit
rate
particularli
surpris
consid
ncc
librari
collect
drug
undergon
multipl
select
screen
numer
differ
librari
collect
librari
exhibit
potent
biolog
activ
variou
diseas
advanc
preclin
clinic
trial
thu
ncc
librari
consist
primarili
screen
winner
anoth
possibl
explan
high
hit
rate
cluster
drug
select
may
target
cellular
pathway
see
supplement
tabl
critic
coronaviru
infect
hand
ssmd
score
system
stringent
tradit
method
use
sd
standard
deviat
cutoff
result
drug
weak
antivir
activ
select
current
screen
case
ribavirin
wellknown
antirna
viru
drug
ssmd
reduct
log
viru
titer
supplement
tabl
fig
thu
high
hit
rate
like
due
util
stringent
ssmd
score
system
summari
identif
candid
anticoronaviru
drug
ncc
librari
current
studi
advanc
discoveri
develop
process
therebi
allow
us
focu
potent
inhibitor
rapidli
priorit
preclin
clinic
trial
particularli
urgent
newli
emerg
merscov
continu
spread
middl
east
rest
world
small
molecul
ncc
drug
librari
screen
found
signific
anticoronaviru
effect
block
viru
entri
other
inhibit
viral
replic
sever
candid
drug
exhibit
robust
antivir
activ
human
divers
anim
coronavirus
micromolar
nanomolar
concentr
without
overt
cytotox
